Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. by Kavanaugh, Arthur et al.
UC San Diego
UC San Diego Previously Published Works
Title
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid 
arthritis.
Permalink
https://escholarship.org/uc/item/1pg6g1jr
Journal
Clinical rheumatology, 37(8)
ISSN
0770-3198
Authors
Kavanaugh, Arthur
Singh, Rakesh
Karki, Chitra
et al.
Publication Date
2018-08-01
DOI
10.1007/s10067-018-4140-0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BRIEF REPORT
Disease activity and biologic use in patients with psoriatic arthritis
or rheumatoid arthritis
Arthur Kavanaugh1 & Rakesh Singh2 & Chitra Karki3 & Carol J. Etzel3 & Joel M. Kremer4 & Jeffrey D. Greenberg3,5 &
Jenny Griffith2
Received: 7 March 2018 /Revised: 2 May 2018 /Accepted: 4 May 2018 /Published online: 4 June 2018
# The Author(s) 2018
Abstract
To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the
Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 andMarch 2013 and
grouped in 2-year intervals. Clinical outcomes and biologic use were assessed. Biologic use increased over time in both cohorts,
with 62 and 52% of patients with PsA and RA, respectively, receiving biologics by 2012–2013. However, 25 and 35% of patients
with PsA and RA, respectively, continued to experience moderate/high disease activity. Overall, the progressive increase in
biologic use accompanied progressive decreases in Clinical Disease Activity Index (from 14.2 to 10.4 for RA, and 12.4 to 8.1 for
PsA) and mean Health Assessment Questionnaire score (from 0.36 to 0.34, and 0.3 to 0.24). Mean patient pain, the proportion of
patients reporting morning stiffness, and the mean duration of morning stiffness remained similar for both cohorts. PsA and RA
treated in the rheumatology setting had a comparable impact on patient quality of life and functional ability. Disease burden
improved with increased biologic utilization in both groups; however, moderate/severe disease remains in a significant propor-
tion of PsA and RA patients.
Keywords Biologics . Disease burden . Psoriatic arthritis . Rheumatoid arthritis
Introduction
Psoriatic arthritis (PsA) is a chronic, progressive, inflammato-
ry arthritis, which affects 20–30% of patients with psoriasis
[1]. Historically, PsAwas considered to be a less severe form
of inflammatory arthritis; however, it has since been demon-
strated that PsA can be associated with substantial joint dam-
age and disability [2].
Cutaneous lesions often precede the appearance of joint
manifestations in PsA, so dermatologists often have the first
opportunity to diagnose and treat [3]. Patients who develop
joint manifestations are then typically referred to a rheumatol-
ogist [3]. One common treatment pathway is for patients to be
offered initial therapy with one or more disease-modifying
antirheumatic drugs (DMARDs), and if this initial treatment
fails, a biologic drug is considered [4].
It is estimated that PsA-related joint erosions and destruc-
tions are similar to those of rheumatoid arthritis (RA) [2],
and yet, although the clinical burden of RA is well
established [5, 6], the clinical burden associated with PsA
is not as adequately quantified [7]. However, evidence sug-
gests that the clinical features of PsA can culminate in re-
duced physical and psychosocial health-related quality of
life and an increased economic burden, with the latter
resulting from direct medical costs and indirect costs due
to disability and lost productivity [7–9].
In this large, real-world study, we directly compared the
disease burden and use of biologic drugs between 2002 and
2013 in patients with PsA or RAwho had been referred to the
rheumatology setting and enrolled in the Consortium of
Rheumatology Researchers of North America (Corrona) reg-
istry. The objective of this analysis was to discover whether
the disease burden of PsA was different from that of RA,
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whether this difference had changed over time, and whether
biologic treatment patterns had altered in the wake of in-
creases in published efficacy and safety data.
Patients and methods
Study design and population
This was a retrospective observational cohort study of patients
with PsA or RA enrolled in the Corrona registry between
January 2002 and March 2013. The ongoing Corrona registry
is an independent, prospective observational cohort of patients
with RA or PsA, recruited from 171 private and academic
practice sites across 40 states in the USA. As of April 2017,
676 rheumatologists and 45,722 patients had participated.
Corrona registry patients aged > 18 years with a PsA or RA
diagnosis and an eligible (last) visit between January 1, 2002
to March 31, 2013 were included in the study. PsA patients
with axial symptoms were excluded from the analysis. Patient
visits during the study period were divided into 2-year inter-
vals and the last visit (enrollment or follow-up visit) for each
patient within the 2-year interval was evaluated.
Outcomes of interest
Disease activity was measured by Clinical Disease Activity
Index (CDAI), physical function was measured using modi-
fied Health Assessment Questionnaire (mHAQ), current bio-
logic use (abatacept, adalimumab, anakinra, certolizumab,
etanercept, golimumab, infliximab, tocilizumab, rituximab),
and individual disease symptoms such as pain (measured
using a visual analog scale (0–100)) and morning stiffness
(% yes, and duration [< 1 or > 1 h]) were assessed and com-
pared between RA and PsA cohorts.
Statistical analysis
Descriptive statistics on patient characteristics were evaluated:
means, standard deviations (quantitative variables), and per-
centages (categorical variables) were presented. Standardized
differences were calculated to compare the distribution of pa-
tient characteristics, both quantitative and categorical, in pa-
tients with RA and PsA across each 2-year time interval.
Logistic regression models were used to estimate adjusted
odds ratio (OR, 95% confidence interval) to evaluate the like-
lihood of a patient having moderate/high disease activity
(based on CDAI) and the use of biologics in patients with
PsA compared to that with patients with RA, adjusting for
covariates within each time period. Covariates used in the
model included age (years), gender (male/female), duration
of disease (years), age at disease onset, education (% with
primary, high school, or college/university), insurance (%
private), comorbidities, current biologic use, and patient loca-
tion (by region).
Results
Demographics and disease characteristics
Patient demographics and disease characteristics are presented
in Table 1. Compared with RA patients, patients with PsA
were, on average, younger and had an earlier disease onset.
A greater proportion of PsA patients had a college/university
education and/or had full-time employment. Although pa-
tients with RA were predominantly female, the PsA cohort
had an equal proportion of males and females.
Disease activity, disability, and biologics use
Over the study period, the use of biologics increased in both
the PsA and RA cohorts, although over time, PsA patients
were > 30% more likely to receive a biologic than their RA
counterparts (OR range from 1.03 to 1.42). By 2012–2013,
62% of patients with PsAwere receiving a biologic compared
with 52% of RA patients (Fig. 1a). The progressive increase in
biologic use was accompanied by a similar progressive de-
crease in overall disease activity over time. The mean CDAI
decreased from 12.4 to 8.1 in the PsA cohort, and from 14.2 to
10.4 in the RA cohort; while disease activity in the patients
with PsA remained slightly lower than that of their RA coun-
terparts (ORs < 1.0 across all time points) (Fig. 1b). Despite
these improvements, 25 and 35% of patients with PsA and
RA, respectively, continued to experience moderate or high
disease activity (CDAI > 10) in the last 2-year interval (2012–
2013) analyzed (Fig. 1c).
The progressive increase in biologic use and decrease in
disease activity was accompanied by a similar progressive
decrease in physical function, with the mean mHAQ in PsA
patients being slightly lower than that of the RA patients over
time (Fig. 2a). Overall, the mean mHAQ decreased from 0.30
to 0.24 in the PsA cohort, and 0.36 to 0.34 in the RA cohort.
However, other patient-reported outcomes such as mean pa-
tient pain (Fig. 2b), the proportion of patients reporting morn-
ing stiffness (Fig. 2c), and the mean duration of morning stiff-
ness (data not shown) remained similar between RA and PsA
patients for the duration of the study.
Discussion
The disease burden associated with RA is well established [5,
6]; the PsA-related burden less so. Our data show that PsA and
RA patients, when treated in the rheumatologist’s office, show
comparable improvements in patient quality of life and
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functional ability. Although joint burden, as measured by
mean CDAI, was slightly lower in PsA patients than that in
RA patients, rheumatologists utilized biologic agents more
frequently among the PsA patients.
Our results show that over the study period, 2002 until
2013, there was an increase in the use of biologic drugs.
Over this same time period, there was a progressive decrease
in disease burden for both RA and PsA. However, by the end
of the study, about a quarter of patients with PsA and one third
of patients with RA continued to experience moderate/high
disease activity.
A delay of 1 year between symptom onset and diagnosis
has been associated with poorer physical function in
established PsA [10], while clinical and radiographic damage
have been shown to be more marked in patients presenting
with > 2 years of disease duration before treatment is initiated
[11, 12]. Peripheral joint erosions and worse functional out-
comes have also been demonstrated with a delay as short as
6 months from symptom onset to the first rheumatology visit
[12]. Therefore, early diagnosis and effective treatment of PsA
may help prevent long-term joint damage and disability.
Some current treatment recommendations for PsA suggest
treatment with anti-inflammatory drugs and a combination of
one or more DMARDs before administering biologic drugs
[4]. However, the efficacy of DMARDs has not been proven
across all of the diverse manifestations of the disease.
Traditional DMARDs have been shown to be ineffective for
the axial manifestations of ankylosing spondylitis, and there
are no data to suggest axial symptoms in PsA patients
would be effectively treated by such agents [13]. For other
manifestations, such as enthesitis and dactylitis, evidence
supporting the clinical efficacy of targeted biological therapies
in PsA is much more robust than that for traditional therapies
[13, 14].
Our study had some limitations. Corrona is an observation-
al registry and its data were restricted to information captured
routinely by US physicians in regular clinical practice (e.g.,
CDAI was evaluated as laboratory measures, a key compo-
nent of other composite indexes used in clinical trials that are
not routinely collected). Additionally, as CDAI is based on a
28-joint count, additional disease impact on joints beyond
those evaluated are not represented. Our registry data were
Fig. 1 Current biologic use (a), mean disease activity (b), and disease
activity by CDAI categories (c) in patients with PsA and RA across the
study period. Covariates used in the models were age, gender, duration of
disease, age of disease onset, education, insurance, comorbidities, current
biologic use (except for a) and region of country. CI, confidence interval;
CDAI, clinical disease activity index; PsA, psoriatic arthritis; RA,
rheumatoid arthritis
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also restricted to assessing the impact of PsA on joints; so
despite measurements being more widespread now, data on
skin involvement and impact of extra-articular manifestations
were not investigated during the study period. Additionally,
the data are from a rheumatology setting, so there may be
referral bias in that PsA patients who require biologics are
more likely to be referred here; there may well be a larger
percentage of untreated patients in community practices. As
with all registries, the characteristics of the enrolled patient
population may not be entirely representative of the entire
patient population. These hypotheses were partly assessed in
a linkage study by Curtis et al., which matched 30,000 records
from RA patients in the Corrona registry with their corre-
sponding Medicare data. As hypothesized above, the authors
found that the Corrona patients were more likely to take
DMARDs and biologic agents, but that other than this differ-
ence, the demographics and comorbidity profiles of these reg-
istry patients were generalizable to the US Medicare popula-
tion [15].
Our study assessment period ended in March 2013. Future
research should focus on evolving trends in the treatment of
PsA since this time and should directly compare the safety and
efficacy of other RA/PsA medications in both the dermatolo-
gy and rheumatology settings.
Fig. 2 Physical function (a),
patient pain (b), and morning
stiffness (c) in patients with PsA
and RA across the study period.
Covariates used in the models
were age, gender, duration of
disease, age of disease onset,
education, insurance,
comorbidities, current biologic
use, and region of country. CI,
confidence interval; mHAQ,
modified Health Assessment
Questionnaire; PsA, psoriatic
arthritis; RA, rheumatoid arthritis;
VAS, visual analog scale
Clin Rheumatol (2018) 37:2275–2280 2279
Conclusions
The overall disease burden of PsA remains slightly lower than
that of RA, but some joint-related symptoms (i.e., pain, morn-
ing stiffness) are comparable. The PsA disease burden report-
ed in the rheumatology setting has decreased during the past
decade, and this appears to have coincided with an increased
use of biologic treatments. However, there continues to be a
substantial proportion of PsA patients with moderate/high dis-
ease activity. Therefore, earlier and more targeted treatment of
PsA joint symptoms may help to improve long-term
outcomes.
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